普利制药富马酸卢帕他定片获国家药品监督管理局批准上市

Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Zhejiang Puli Pharmaceutical Co., Ltd., has received the drug registration approval for Fumaric Acid Lurasidone Tablets from the National Medical Products Administration (NMPA), marking a significant step for market expansion in China [1] Company Summary - The approved allergy medication, Fumaric Acid Lurasidone Tablets, is branded as Fubiding®, adding a new heavyweight product to the allergy treatment sector [1]